Cagrilintide vs Eloralintide: What the Research Compares

Cagrilintide and eloralintide are investigational medicines in clinical trials, studied as long-acting agonists at amylin receptor pathways for obesity and related metabolic conditions. Published reviews of this class placed both compounds inside the same emerging category of amylin-based pharmacotherapy while describing them as separate development programs with separate trial datasets (PMID 42452898, PMID 42803913). This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, including anything described in the studies summarised here.

Is there a head-to-head randomized trial?

No published randomized controlled trial has enrolled a single population and randomized participants to cagrilintide versus eloralintide. Reviews that catalogued the amylin analog pipeline in 2026 described the clinical programs for these agents in separate sections, with separate study populations and separate comparator arms, rather than within one shared protocol (PMID 42452898, PMID 41747885). Because of that, any statement ranking one against the other would not be supported by the published record, and this page does not make one.

The closest published approach to a comparison is indirect. A network meta-analysis of novel amylin-based therapies for weight management in adults with overweight or obesity without diabetes pooled trials of the class and used statistical modelling to compare agents that had never met in the same trial (PMID 42175595). Indirect comparisons of that kind depend on how similar the underlying trial populations, durations and background treatments were, and the authors of the analysis framed the work as a synthesis of early evidence rather than as a substitute for a direct trial (PMID 42175595).

Side-by-side summary of the published evidence bases

Shared mechanism: what amylin receptor agonism means in the literature

Amylin is a pancreatic hormone co-secreted with insulin, and reviews of amylin-related peptides described the therapeutic rationale as reproducing amylin signalling with molecules engineered to last far longer than the native hormone (PMID 41747885). The same reviews described the central effects of this signalling on meal-related satiation pathways as the basis for studying these peptides in obesity and type 2 diabetes (PMID 41747885, PMID 42803913).

Within the class, published pharmacology reviews drew distinctions between agents according to how selectively they engage amylin receptor complexes compared with related calcitonin receptor signalling, and framed receptor selectivity as one of the variables under investigation across different molecules (PMID 42452898, PMID 42586227). The eloralintide program was reported as a discovery effort built around amylin receptor agonism carried through to clinical proof of concept (PMID 41109426), while cagrilintide was reviewed among the long-acting amylin-related peptides developed for the same broad indications (PMID 41747885).

Why mechanism alone does not settle a comparison

Two molecules in one pharmacological class can differ in receptor selectivity, half-life, formulation and the trial designs used to test them, and reviews of obesity pharmacotherapy emphasised that such differences shaped the reported outcomes across programs (PMID 41948476). Because the published trials for these two agents differed in population, duration and comparator, the reviews presented their results descriptively rather than as a league table (PMID 42452898).

What the cagrilintide literature reports

Cagrilintide appeared in 2026 reviews as one of the long-acting amylin-related peptides advanced into clinical study for obesity and type 2 diabetes, with the reviews summarising body weight and glycaemic endpoints across the class rather than reporting a single defining trial (PMID 41747885, PMID 42803913). Reviews of multi-receptor obesity pharmacotherapy also discussed amylin analogs combined with incretin-based medicines, describing combination development as a major theme of the current research era (PMID 41948476).

The network meta-analysis of amylin-based therapies in adults with overweight or obesity without diabetes included agents from this class and reported weight-related outcomes using indirect comparison methods (PMID 42175595). Readers comparing agents should note that the analysis drew on trials of differing length and design, a limitation the authors addressed in framing the certainty of the pooled estimates (PMID 42175595).

What the eloralintide literature reports

The published eloralintide report described the molecule as LY3841136 and traced it from preclinical discovery through early clinical study in obesity, with the authors presenting the program as reaching clinical proof of concept (PMID 41109426). That paper sits earlier on the evidence timeline than the large multi-trial datasets that accumulate around later-stage programs, which is one practical reason the published comparison between these two agents remains uneven (PMID 42452898).

Class reviews published in 2026 included eloralintide among the newer amylin-based agonists under investigation and discussed selective amylin receptor agonism as a design strategy being tested in obesity and type 2 diabetes (PMID 42803913, PMID 42586227).

Regulatory status

Both compounds are described in the published literature as investigational agents evaluated in clinical trials, meaning that human exposure occurs inside trial protocols under regulatory and ethical oversight, and that marketing authorisation decisions rest with national regulators such as the FDA and EMA (PMID 42452898, PMID 41109426). Reviews of the amylin class framed these programs as candidates in active development alongside approved incretin-based medicines (PMID 41948476). Any question about availability, eligibility or appropriateness is a clinical and regulatory matter for a licensed prescribing clinician.

Adverse Events: What Studies Report

Across the amylin class, reviews reported gastrointestinal effects as the adverse events described most often, with nausea and vomiting leading the published tolerability profiles in early-phase trials (PMID 42452898, PMID 42586227). Reviews of amylin-based pharmacotherapy framed tolerability as a central research question for the class, noting that trial programs were designed partly to characterise how gastrointestinal effects compared with those seen with incretin-based agents (PMID 42586227).

Additional points the reviews raised about safety reporting in this class included the following:

• Injection-site reactions and gastrointestinal symptoms were described among the events reported in trials of long-acting amylin-related peptides (PMID 41747885).
• Reviews noted that early-phase trials were short and modest in size, so uncommon events and long-term outcomes remained incompletely characterised (PMID 42452898).
• Combination research with incretin-based medicines raised separate tolerability questions that reviewers treated as distinct from monotherapy data (PMID 41948476).
• The network meta-analysis reported adverse event outcomes alongside weight outcomes for amylin-based therapies in adults with overweight or obesity without diabetes (PMID 42175595).

How to read this comparison

A fair reading of the current record separates three things. First, the absence of a direct trial means any comparative claim about the two agents rests on indirect methods rather than randomization, as the published network meta-analysis made explicit in its design (PMID 42175595). Second, the two programs occupy different points on the development timeline, with eloralintide reported at the proof-of-concept stage (PMID 41109426) and cagrilintide discussed within broader reviews of long-acting amylin peptides (PMID 41747885). Third, class-level tolerability findings described in reviews apply to the category and were not reported as a resolved comparison between these two specific molecules (PMID 42586227).

Published evidence in this area is moving quickly, and reviews written in 2026 described the amylin field as early and evolving (PMID 42803913). Conclusions drawn today may be revised as larger and longer trials report.

Related reading

• Cagrilintide: what the published research describes
• Eloralintide: what the published research describes

References

• Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept (Molecular Metabolism, 2025)
• Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes (Peptides, 2026)
• Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials (Diabetes, Obesity & Metabolism, 2026)
• Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs (Pharmacological Research, 2026)
• Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies (Metabolism Open, 2026)
• New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus (Diabetes Therapy, 2026)
• Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis (Endocrinology, Diabetes & Metabolism, 2026)